Ibalizumab vs Tofacitinib

## Ibalizumab vs Tofacitinib: Overview

This comparison examines the pharmacological differences between **Ibalizumab** and **Tofacitinib**.

## Mechanism of Action

**Tofacitinib**: Pan-JAK inhibitor with preference for JAK1 and JAK3 blocking pro-inflammatory cytokine signaling.

## Pharmacokinetics

**Half-life**: Ibalizumab — N/A; Tofacitinib — 3.2 hours.

## Chemical Properties

**Molecular Formula**: Ibalizumab — N/A; Tofacitinib — C16H20N6O.

**Molecular Weight**: Ibalizumab — N/A; Tofacitinib — 312.3700 g/mol.

**Type**: Ibalizumab — Antibody; Tofacitinib — Small molecule.